Advocacy – Talk Bio

Sanofi Contributes to Report Emphasizing Importance of Sustainably Paid Community Health Workers

2 weeks ago talkbio0Tagged Advocacy, CHW Access Act, Community Health Workers, digital infrastructure, Health Equity, National Association of, Policy, sanofi, sustainability

Sanofi; community health workers; sustainability; health equity; National Association of Community Health Workers; policy advocacy; digital infrastructure; CHW Access Act

FDA Union Prepares for Negotiations as HHS Job Cuts Reshape Workforce

5 months ago talkbio0Tagged Advocacy, CHARGE Syndrome, employee layoffs, federal, Force, layoffs, Mediation, public health medicine (field), reduction in force, restructuring, Union, United States Food and Drug Administration

FDA layoffs, HHS restructuring, Union negotiations, Reduction in Force (RIF), Robert F. Kennedy Jr., FDA workforce reduction, HHS employee layoffs, Federal health agencies, Public health impact, Union advocacy

Trump Administration Considers Cuts to CDC’s HIV Prevention Program, Raising Concerns

6 months ago talkbio0Tagged Acquired Immunodeficiency Syndrome, Administration occupational activities, Advocacy, Centers for Disease Control and Prevention (U.S.), Funding, HIV Prevention, public health medicine (field), Transplant Registry Unified Management Program

HIV prevention, CDC funding cuts, Trump administration, public health, HIV/AIDS advocacy

Celebrating Visionaries: Insights from the 2024 Fierce 50 Honorees

9 months ago talkbio0Tagged 2024, Advocacy, Biopharma, Fierce, Health Equity, healthcare innovation, honorees

Fierce 50, 2024 Honorees, Healthcare Innovation, Biopharma, Health Equity, Patient Advocacy

Controversy Surrounds FDA’s Fast-Track Approval of Sarepta’s Duchenne Muscular Dystrophy Gene Therapy

1 year ago talkbio0Tagged Accelerated, Advocacy, Approved, Clinical Trials, DMD, Duchenne, Effectiveness, gene therapy, Muscular Dystrophy, Muscular Dystrophy, Duchenne, Regulation of biological process, Safety, United States Food and Drug Administration

FDA, Sarepta Therapeutics, Duchenne Muscular Dystrophy (DMD), gene therapy, accelerated approval, controversy, clinical trials, efficacy, safety, patient advocacy, regulatory process.